This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index...read more
Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, raised $36 million by offering 4 million shares at $9, below the range of $10 to $12. Xenon Pharmaceuticals plans to list on the NASDAQ under the symbol XENE....read more
Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, relaunched its IPO on Monday, two weeks after initially postponing its deal in. The Burnaby, Canada-based company still plans to raise $44 million by offering 4...read more
Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, postponed its IPO on Friday, citing poor market conditions. The Burnaby, Canada-based company was founded in 1996 and booked $27 million in sales for the 12...read more
US IPO Weekly Recap: 8 companies go public with strong returns as 5 delay IPOs
This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index...read more
Xenon Pharmaceuticals prices IPO at $9, below the range
Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, raised $36 million by offering 4 million shares at $9, below the range of $10 to $12. Xenon Pharmaceuticals plans to list on the NASDAQ under the symbol XENE....read more
Xenon Pharmaceuticals relaunches $44 million IPO
Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, relaunched its IPO on Monday, two weeks after initially postponing its deal in. The Burnaby, Canada-based company still plans to raise $44 million by offering 4...read more
Xenon Pharmaceuticals postpones IPO
Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, postponed its IPO on Friday, citing poor market conditions. The Burnaby, Canada-based company was founded in 1996 and booked $27 million in sales for the 12...read more